Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
- PMID: 35260039
- PMCID: PMC8920354
- DOI: 10.1080/0886022X.2022.2047069
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
Abstract
Kidney transplantation is the treatment of choice in end-stage renal disease. The main issue which does not allow to utilize it fully is the number of organs available for transplant. Introduction of highly effective oral direct-acting antivirals (DAAs) to the treatment of chronic hepatitis C virus infection (HCV) enabled transplantation of HCV viremic organs to naive recipients. Despite an increasing number of reports on the satisfying effects of using HCV viremic organs, including kidneys, they are more often rejected than those from HCV negative donors. The main reason is the presence of HCV viremia and not the quality of the organ. The current state of knowledge points to the fact that a kidney transplant from an HCV nucleic acid testing positive (NAT+) donor to naive recipients is an effective and safe solution to the problem of the insufficient number of organs available for transplantation. It does not, however, allow to draw conclusions as to the long-term consequence of such an approach. This review analyzes the possibilities and limitations of the usage of HCV NAT + donor organs. Abbreviations: DAA: direct-acting antivirals; HCV: hepatitis C virus; NAT: nucleic acid testing; OPTN: Organ Procurement and Transplantation Network; KDIGO: Kidney Disease: Improving Global Outcomes; Ab: antigen; eGFR: estimated glomerular filtration rate; D: donor; R: recipient; CMV: cytomegalovirus; HBV: hepatitis B virus; UNOS: United Network for Organ Sharing; PHS: Public Health Service; EBR/GZR: elbasvir/grazoprevir; SVR: sustained virologic response; RAS: resistance-associated substitutions; SOF: soforbuvir; GLE/PIB: glecaprevir/pibrentasvir; ACR: acute cellular rejection; AR: acute rejection; DSA: donor-specific antibodies; KTR: kidney transplant recipients; AASLD: American Association for the Study of Liver Disease; IDSA: Infectious Diseases Society of America; PPI: proton pump inhibitors; CKD: chronic kidney disease; GN: glomerulonephritis; KAS: The Kidney Allocation system.
Keywords: Renal transplantation; antiviral drugs; hepatitis C; organ donors.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
References
-
- Organ Procurement and Transplantation Network [accessed May 4, 2021]. Available from: http://optn.transplant.hrsa.gov.
-
- Tong J, Liu M, Li H, et al. Mortality and associated risk factors in dialysis patients with cardiovascular disease. Kidney Blood Press Res. 2016;41(4):479–487. - PubMed
-
- Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2017 annual data report: kidney. Am J Transplant. 2019;19:19–123. - PubMed
-
- Rudd RA, Seth P, David F, et al. Increases in drug and Opioid-Involved overdose deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445–1452. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous